Boston Scientific Investors Face May 4 Deadline in Securities Class Action

The filing follows February results that undercut growth expectations, sending shares down about 18%.

Overview

Filed as Troike v. Boston Scientific, No. 26-cv-40075 (D. Mass.), the suit names the company and certain executives for alleged Securities Exchange Act violations.
The complaint alleges investors were misled about the reliability of revenue projections and competitive pressures in the U.S. electrophysiology market.
The putative class period spans July 23, 2025 through February 3, 2026.
Investors have until May 4, 2026 to seek appointment as lead plaintiff, with Robbins Geller and Pomerantz soliciting claimants and the Frank R. Cruz firm issuing a deadline notice.
On February 4, 2026, Boston Scientific posted Q4 GAAP EPS of $0.45 versus its $0.48–$0.52 guidance and cited slower market growth and heightened competition, after which BSX fell 17.6% to $75.50.